CRH抗体—艾普蒂

Corticotropin-releasing hormone (CRH) antibodies are immunological tools designed to target CRH, a 41-amino-acid neuropeptide central to the hypothalamic-pituitary-adrenal (HPA) axis. CRH, primarily synthesized in the hypothalamus, regulates adrenocorticotropic hormone (ACTH) release from the pituitary, thereby influencing glucocorticoid production and stress responses. Dysregulation of CRH signaling is implicated in stress-related disorders (e.g., depression, anxiety), metabolic syndromes, and inflammatory conditions. CRH antibodies are pivotal in research for detecting CRH expression, localization, and function in tissues, often via immunohistochemistry, ELISA, or Western blot. They also enable mechanistic studies by neutralizing CRH activity in vitro or in vivo, helping dissect its roles in stress physiology, immune modulation, and reproductive functions. Clinically, CRH antibody-based assays aid in diagnosing Cushing’s syndrome, adrenal insufficiency, or HPA axis abnormalities. Some therapeutic strategies explore CRH antibodies to mitigate pathological CRH overactivity, though clinical applications remain experimental. These antibodies are typically raised in hosts like rabbits or mice, with specificity validated against conserved regions of human or rodent CRH. Challenges include cross-reactivity with related peptides (e.g., urocortins) and ensuring sensitivity in complex biological matrices. Overall, CRH antibodies serve as essential reagents for unraveling CRH’s multifaceted roles and developing diagnostic or therapeutic interventions targeting HPA axis disorders.